Across TCGA pan-cancer cohorts, ASTL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ASTL data layer compared with 23 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher ASTL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ASTL expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

PRAD, STAD, and UCEC are the cancer types where ASTL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.422	0.888	<.001	6	view →
STAD	DFS	Median	III,IV	1.000	0.333	.039	5	view →
UCEC	DFS	Median	All	1.000	0.630	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ASTL tumor-vs-normal RNA expression · all ASTL data types